. 2022 Sep 8;122(2):121–131. doi: 10.1016/j.jfma.2022.09.004

Table 3.

Neutralising antibody responses of the study subjects before and 28 days after receiving the third-dose of the mRNA vaccine.

	Variants of concern	Group 1 Full-dose mRNA-1273, NT₅₀ (IU/mL) (n = 100)	Group 2 Half-dose mRNA-1273, NT₅₀ (IU/mL) (n = 98)	Group 3 Full-dose BNT-162b2, NT₅₀ (IU/mL) (n = 100)	P values
	Variants of concern	Group 1 Full-dose mRNA-1273, NT₅₀ (IU/mL) (n = 100)	Group 2 Half-dose mRNA-1273, NT₅₀ (IU/mL) (n = 98)	Group 3 Full-dose BNT-162b2, NT₅₀ (IU/mL) (n = 100)	Group 1 vs. Group 2	Group 1 vs. Group 3	Group 2 vs. Group 3
Day 1	Alpha	13.06 (7.34–23.22)	28.35 (18–44.65)	22.2 (12.81–38.46)	0.0366	NS	NS
	Delta	4.18 (2.35–7.46)	11.64 (6.74–20.12)	6.43 (3.63–11.4)	0.0186	NS	NS
	Omicron	1 (1.00–1.00)	1 (1.00–1.00)	1 (1.00–1.00)	NS	NS	NS
Day 28	Alpha	2262 (1931–2649)	2041 (1672–2492)	1549 (1326–1810)	NS	0.0006	NS
	Fold change	173.23	72.00	69.80	0.0028	0.0008	NS
	Delta	1358 (1148–1606)	1228 (1015–1486)	853 (708–1029)	NS	0.0003	0.0126
	Fold change	324.63	105.47	132.69	0.0029	0.0091	NS
	Omicron	222 (185–267)	175 (142–217)	135 (106–173)	NS	0.0011	NS
	Fold change	222.37	175.30	135.36	NS	0.0011	NS

Abbreviation: NS, not significant.